Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » 85% - OPERATING INCOME

This excerpt taken from the EYE 8-K filed Oct 31, 2008.

Operating Income

 

  •  

$26.6 million; represented 9.7% of sales, compared to a loss of $6.7 million in the year-ago period.

 

  •  

Included $29.3 million in total depreciation and amortization, compared to $27.3 million in total depreciation and amortization in the year-ago period.

 

  •  

Included $5.9 million in stock-based compensation expense, compared to $5.7 million in the year-ago period.

 

3

This excerpt taken from the EYE 8-K filed Aug 4, 2008.

Operating Income

 

  •  

$58.1 million, represented 18.1% of sales.

 

  •  

Included $11.0 million in restructuring and related charges.

 

  •  

Included a $20.5 million net gain on legal contingencies associated with a cross-licensing agreement.

 

  •  

Included $29.2 million in total depreciation and amortization, of which $17.2 million was intangible amortization, compared to $26.4 million in total depreciation and amortization, of which $16.8 million was intangible amortization in the year-ago period.

 

  •  

Included $6.2 million in stock-based compensation expense, compared to $5.1 million in the year-ago period.

 

3

  •  

Year-ago loss of $127.9 million included an $85.4 million in-process R&D charge and $22.2 million in transaction-related charges primarily related to the IntraLase acquisition, as well as costs and impacts associated with the May 2007 recall.

This excerpt taken from the EYE 8-K filed May 1, 2008.

Operating Income

 

  •  

Rose 7.8% to $29.4 million; represented 9.7% of sales.

 

  •  

Included $11.9 million in restructuring charges related to manufacturing consolidation and headcount reductions.

 

  •  

Included $28.0 million in total depreciation and amortization, of which $17.1 million was intangible amortization, compared to $17.1 million in total depreciation and amortization, of which $9.9 million was intangible amortization, in the year-ago period.

 

  •  

Included $5.1 million in stock-based compensation expense, compared to $4.7 million in the year-ago period.

 

  •  

Year-ago operating income included a $1.6 million in-process R&D charge related to acquisitions.

This excerpt taken from the EYE 10-K filed Mar 14, 2006.
Operating income. Operating income (loss) was $(411.3) million, $33.0 million and $59.5 million in 2005, 2004 and 2003, respectively. Our 2005 operating loss was negatively impacted by an aggregate $559.9 million in charges primarily related to the VISX Acquisition and our product rationalization and business repositioning initiatives as discussed above.

 

This excerpt taken from the EYE 10-Q filed Apr 29, 2005.

85% - OPERATING INCOME

 

PERFORMANCE LEVEL

    2005 OP
INCOME
RANGE
    BONUS
AWARD AS A
% OF TARGET

Below Threshold

    -44.56 mm    0%

Threshold

    -44.55 mm    40%
     Target    100%

Maximum

    +22.28 mm    150%

 

If actual Operating Income results fall between the performance levels shown above, the portion of bonus will be prorated accordingly.

 

EXCERPTS ON THIS PAGE:

8-K
Oct 31, 2008
8-K
Aug 4, 2008
8-K
May 1, 2008
10-K
Mar 14, 2006
10-Q
Apr 29, 2005

RELATED TOPICS for EYE:

"85% - OPERATING INCOME" elsewhere:

BECTON DICKINSON & CO (BDX)
Cooper Companies (COO)
Haemonetics (HAE)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki